Your browser doesn't support javascript.
loading
MABp1 targeting interleukin-1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period.
Kanni, T; Argyropoulou, M; Dinarello, C A; Simard, J; Giamarellos-Bourboulis, E J.
Affiliation
  • Kanni T; Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Argyropoulou M; Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Dinarello CA; Department of Medicine, The University of Colorado in Denver, Denver, CO, USA.
  • Simard J; XBiotech, Austin, TX, USA.
  • Giamarellos-Bourboulis EJ; Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Clin Exp Dermatol ; 46(1): 162-163, 2021 Jan.
Article in En | MEDLINE | ID: mdl-32516832
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hidradenitis Suppurativa / Eligibility Determination / Antibodies, Monoclonal Type of study: Clinical_trials Aspects: Patient_preference Limits: Humans Language: En Journal: Clin Exp Dermatol Year: 2021 Document type: Article Affiliation country: Greece Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hidradenitis Suppurativa / Eligibility Determination / Antibodies, Monoclonal Type of study: Clinical_trials Aspects: Patient_preference Limits: Humans Language: En Journal: Clin Exp Dermatol Year: 2021 Document type: Article Affiliation country: Greece Country of publication: United kingdom